DENVER — Three manuscripts published
in the recent issue of the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (IASLC), explored the versatility of liquid biopsies by identifying EGFR mutations using circulating
tumor DNA (ctDNA)
in urine and plasma and examining circulating
tumor cells (CTCs)
in plasma to predict the risk of lung cancer recurrence after surgical
resection.